Sequana Medical NV is a Belgian medical device company headquartered in Ghent, Belgium, focused on innovative treatments for fluid overload conditions associated with liver disease, heart failure, and malignant ascites. The company was founded in 2006 and is listed on Euronext Brussels under the ticker symbol SEQUA, with a market capitalization of approximately €43.56 million as of April 28, 2026. Sequana Medical's primary product is the alfapump®, a fully implantable, programmable, wirelessly charged, battery-powered system designed to manage refractory liver ascites and malignant ascites. The alfapump® is CE-marked for use in patients with refractory ascites due to liver cirrhosis and in cases of malignant ascites where the patient has a life expectancy of six months or less. In February 2019, the company raised €27.5 million through an initial public offering, which gave it an initial market capitalization of €107.2 million. As of 2024, Sequana Medical reported a turnover of €105,500 and a net loss of €44.65 million. The company’s management team includes CEO Ian Crosbie, CFO Kirsten Van Bockstaele, and Chief Medical Officer Dr. Gijs Klarenbeek. As of 2026, Sequana Medical employs approximately 48 individuals. The company has received investments from PMV, a cornerstone investor in its IPO, and has participated in follow-on investments from 2020 to 2022.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Sequana Medical's offering is currently approved on OTHER. Sequana Medical is headquartered in Belgium. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Sequana Medical.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/sequana-medical" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Sequana Medical — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/sequana-medical?theme=light as the src instead.
https://www.discoveripo.com/ipo/sequana-medical/opengraph-image
Sequana Medical IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/sequana-medical?utm_source=embed&utm_medium=text&utm_campaign=sequana-medical
Get emailed when Sequana Medical's terms, price, or expected date change — no weekly noise, just this company.
Sequana Medical is listing on OTHER.
Sequana Medical NV is a Belgian medical device company headquartered in Ghent, Belgium, focused on innovative treatments for fluid overload conditions associated with liver disease, heart failure, and malignant ascites. The company was founded in 2006 and is listed on Euronext Brussels under the ticker symbol SEQUA, with a market capitalization of approximately €43.56 million as of April 28, 2026. Sequana Medical's primary product is the alfapump®, a fully implantable, programmable, wirelessly charged, battery-powered system designed to manage refractory liver ascites and malignant ascites. The alfapump® is CE-marked for use in patients with refractory ascites due to liver cirrhosis and in cases of malignant ascites where the patient has a life expectancy of six months or less. In February 2019, the company raised €27.5 million through an initial public offering, which gave it an initial market capitalization of €107.2 million. As of 2024, Sequana Medical reported a turnover of €105,500 and a net loss of €44.65 million. The company’s management team includes CEO Ian Crosbie, CFO Kirsten Van Bockstaele, and Chief Medical Officer Dr. Gijs Klarenbeek. As of 2026, Sequana Medical employs approximately 48 individuals. The company has received investments from PMV, a cornerstone investor in its IPO, and has participated in follow-on investments from 2020 to 2022.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy